Drugs / Benfo-oxythiamine
Benfo-oxythiamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07450833 | Mar → Nov 2022 | — | Benfovir AG | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Benfo-oxythiamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07450833 ↗ |
| Action | Inhibit | “Upon ingestion, it releases oxythiamine to inhibit transketolase enzymes.” NCT07450833 ↗ |
| Route | Oral | “B-OT is administered orally once daily for 7 consecutive days.” NCT07450833 ↗ |
| Target | TKT | “Its primary therapeutic targets are Transketolase (TKT) and Transketolase-like 1 (TKTL1)” NCT07450833 ↗ |
| Target | TKTL1 | “Its primary therapeutic targets are Transketolase (TKT) and Transketolase-like 1 (TKTL1)” NCT07450833 ↗ |